Thalys Medical Technology

What Thalys Medical Technology does

Thalys Medical Technology (塞力斯医疗科技集团股份有限公司, Shanghai Stock Exchange ticker 603716.SH) is a Chinese healthcare services and medical supply chain company headquartered in Wuhan that focuses on hospital-facing centralized services rather than direct clinical care. Founded in 2008, the firm reports 1,001–5,000 employees and operates across three core service lines: SPD (Supply, Processing and Distribution) centralized operation services for medical consumables procurement, distribution, inventory management, and centralized settlement; IVD (in vitro diagnostics) centralized operation services covering reagent procurement, equipment maintenance, informatization, and ISO15189 certification support; and co-built regional medical testing centers delivered via joint ventures with local government-owned investors such as Lianzhou Jiarun Investment Group (e.g., 65%/35% JV with a 3-year, 150 million RMB Lianzhou Regional Testing Center contract).

The company's commercial model is anchored in enterprise field sales into municipal and regional hospitals, primarily winning business through formal public-sector procurement bidding. Approximately five SPD projects are concentrated in Yixing alone, and the company claims nationwide provincial coverage of its supply chain network. Beyond service revenue, Thalys operates a self-developed IVD reagent product line centered on coagulation diagnostics and expanding into chemiluminescence, rapid testing, and flow cytometry, alongside a distribution/agency business for partner-manufactured diagnostic products. In June 2026 the company launched AIRATA (智微敏鉴™), a proprietary anti-infection AI vertical model supporting antimicrobial resistance decision-making, marking a stated strategic pivot toward smart hospital AI digital construction — though the legacy services book remains the dominant revenue engine and the firm's headline revenue series shows a multi-year decline through 2025 with negative EBITDA, operating losses since 2022, and widening net losses.

Name

Thalys Medical Technology

Legal name

塞力斯医疗科技集团股份有限公司

Website

https://thalys.net.cn

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Thalys Medical Technology (603716.SH) is a Wuhan-headquartered Chinese healthcare services company providing SPD medical consumables centralized services, IVD procurement and lab operations, and co-built regional testing centers to government-backed hospitals, alongside self-developed IVD reagents and the AIRATA anti-infection AI model.

Ownership category

akta.pro rank

Product category

Medical Supply Chain Services

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Medical Equipment and Supplies Manufacturing (3391)

SIC

Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071)

akta.pro primary industry

Sterile Processing / Central Sterile Services (SPD/CSSD) (HLAFAIAN)

akta.pro secondary industries

Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI), Diagnostic & Triage Decision Support (HLACAGAA), Interoperability Standards, Profiles & Implementation (HL7/FHIR/IHE) (HLACABAA), Medical Devices & Diagnostics Temperature-Controlled Storage (TLALABAH)

Keywords

• Medical supply chain
• SPD centralized services
• IVD distribution
• Regional medical testing
• Smart hospital digitization

Headquarters

HQ city

Wuhan Shi

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. SPD集约化服务: Provides medical consumables centralized procurement, distribution, inventory management, centralized settlement, and department operational performance analysis for medical institutions. Revenue generated through service fees and supply chain management charges.
2. IVD集约化服务: IVD centralized procurement supply and distribution, equipment maintenance, informatization construction, ISO15189 certification support. Revenue from procurement services and ongoing operational support contracts.
3. 区域检验中心共建: Co-construction and operation of regional testing centers, with 3-year service contracts (e.g., Lianzhou project at 150 million RMB). Generates recurring service revenue from long-term operational partnerships.
4. 自研产品销售: Sales of self-developed IVD reagents and diagnostic products including coagulation, chemiluminescence, and rapid testing products.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Thalys Medical Technology provides SPD (Supply, Processing and Distribution) centralized services for medical consumables—covering procurement, distribution, inventory management, settlement, and department performance analysis—and IVD (In Vitro Diagnosis) integrated services, including equipment maintenance, informatization, and ISO15189 certification support. It also co-constructs and operates regional medical testing centers, and develops self-owned diagnostic reagents (coagulation, chemiluminescence, rapid testing, flow cytometry) alongside the AIRATA anti-infection AI model.

Product overview

Thalys Medical Technology operates a unified smart hospital digital construction platform combining medical centralized services with AI-powered solutions. The core portfolio includes SPD centralized operation services (medical supplies procurement, distribution, inventory management, and settlement), IVD centralized operation services (in vitro diagnostic products, equipment maintenance, and informatization), and jointly-built regional testing centers. Supporting these are self-developed diagnostic products (coagulation, chemiluminescence, rapid testing, flow cytometry) and distributed agency products from global partners. The platform is enhanced by the proprietary AIRATA anti-infection AI model for clinical decision support, representing the company's strategic transformation toward AI-enabled smart hospital services.

Differentiator

Problem solved

Functional benefit

Brands

• AIRATA (智微敏鉴): AI anti-infection model launched in June 2026 for clinical anti-infection scenarios
• SPD集约化服务
• IVD集约化服务

Products and services

• SPD Centralized Operation Services (SPD集约化运营服务) Provides one-stop centralized services for medical consumables, including procurement, distribution, inventory management, centralized settlement, department operational performance analysis, and supply chain finance, delivered to hospitals and medical institutions to reduce costs and improve efficiency.
• IVD Centralized Operation Services (IVD集约化运营服务)
• Joint Regional Testing Center Co-Construction (合作共建区域检验中心)
• Self-Developed Diagnostic Reagent Products (自研产品)
• Agency / Distribution Diagnostic Products (代理产品)
• Smart Healthcare / AI Solutions (智慧医疗) — including AIRATA Anti-Infection AI Model

Quantifiable outcome

• Cost reduction through centralized procurement and lean management
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

One partnership is on record.

• 连州市嘉润投资集团有限公司coreStrategic or Co-development Partner · 16 June 2026Joint venture partnership for Lianzhou Regional Medical Testing Center. Thalys holds 65% stake while Lianzhou Jiarun Investment Group holds 35%. This represents a deep co-construction model transitioning from early project participation to long-term operational partnership with government backing.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Da An Gene (Kingstar Genomics): Chinese IVD and molecular diagnostics company with strong reagent portfolio. Comparable to Thalys in IVD reagent manufacturing and hospital channel distribution.
• Autobio Diagnostics: Chinese IVD manufacturer with broad chemiluminescence, microbiology, and clinical chemistry portfolio. Directly comparable to Thalys' self-developed IVD ambitions, particularly the chemiluminescence and rapid testing pipelines.
• KingMed Diagnostics: China's largest independent third-party medical testing laboratory network. Directly comparable to Thalys' regional testing center co-construction and IVD service business, with established national logistics and result-interoperability infrastructure.

Broad incumbents

• Sinopharm Group: China's largest state-owned pharmaceutical and medical device distributor. Directly comparable to Thalys' SPD/IVD distribution and managed services business, but at far greater scale and with deeper government relationships.
• Mindray Medical International: Leading Chinese medical device and IVD manufacturer with global reach. Comparable to Thalys through its IVD reagent and instrument business and its engagement with hospital purchasing channels, though vertically integrated into manufacturing.
• Lepu Medical Technology: Chinese cardiovascular and IVD medical device company with hospital-direct sales model. Comparable to Thalys through hospital channel relationships and IVD reagent offerings, with broader interventional device portfolio.
• Shanghai Pharmaceuticals Holding: One of China's largest pharmaceutical distributors with listed entity on SSE/HKEX. Comparable to Thalys in distribution and supply chain services to medical institutions, with broader drug and device portfolio.
• China Resources Pharmaceutical Group: State-backed pharmaceutical and medical supply distributor with nationwide reach. Comparable to Thalys in hospital supply chain centralization, with stronger capital backing and broader product portfolio.

Emerging players

• BGI Genomics: Chinese genomics and molecular diagnostics leader with both products and testing services. Comparable to Thalys' regional testing center model and IVD ambitions, with stronger focus on genomic/sequencing diagnostics.
• Beijing Strong Biotechnologies: Chinese clinical chemistry and IVD reagent company. Comparable to Thalys in IVD reagent development and distribution, but at smaller scale and narrower diagnostic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Thalys Medical Technology